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Salt intake determines the renal response to L-arginine infusion in
normal human subjects. Studies in experimental animals have shown that
nitric oxide (NO) generation in the kidney from L-arginine participates in
adapting renal function to changes in salt intake, but similar studies in
human subjects are lacking. Therefore, we compared the infusion of 30 g
of L-arginine to 30 g of branched chain amino acids (control), in eight
normal human subjects after 5 to 7 days of equilibration to a low salt (LS;
20 mmol z 24 hr21) or high salt (HS; 200 mmol z 24 hr21) intake. Lithium
clearance was used as a marker of proximal tubular reabsorption. Com-
pared to the control infusions, L-arginine did not significantly alter blood
pressure, inulin or paraaminohippurate clearance, but significantly in-
creased (P , 0.05) the excretion of NO2 1 NO3 (NOx) (LS, 157 6 46 to
210 6 48 nmol z min21; HS, 138 6 30 to 182 6 70) and cGMP (LS, 253 6
63 to 337 6 76 pmol z min21; HS, 311 6 68 to 563 6 52). Renal sodium
excretion was decreased by L-arginine infusion during the low salt intake
(45 6 5 to 21 6 3 mmol z min21; P , 0.05) but was increased by L-arginine
during the high salt intake (298 6 56 to 537 6 84 mmol z min21; P , 0.05).
The calculated fractional reabsorption of sodium in the proximal and
distal nephrons, as assessed from lithium and sodium clearances, was
increased by L-arginine during the low salt intake but was decreased by
L-arginine during the high salt intake. L-arginine increased plasma insulin
concentration significantly (P , 0.05). This effect was independent of salt
intake (LS, 67 6 7 to 92 6 13 ng z ml21; HS, 66 6 7 to 76 6 9 ng z ml21).
L-arginine did not significantly alter plasma renin activity. In conclusion,
L-arginine increases the excretion of NOx and cGMP and increases
plasma insulin, but the effect on sodium excretion depends upon salt
intake. L-arginine enhances Na reabsorption in the proximal and distal
nephrons during the low salt intake, but inhibits it during the high salt
intake. Effects of L-arginine on NO and cGMP may contribute to its
effects on Na reabsorption.
L-arginine is formed from L-citrulline in the proximal tubule of
the kidney [1, 2]. It can be metabolized by a family of nitric oxide
synthase (NOS) isoforms to citrulline and nitric oxide (NO). In
the kidney, NO is a powerful vasodilator [3], and blunts the
expression of the tubuloglomerular feedback (TGF) response [4,
5] and the action of vasoconstrictors such as angiotensin II (Ang
II) [6]. Some studies have shown that NO, or its second messen-
ger, cyclic guanosine monophosphate (cGMP), can inhibit sodium
uptake or reabsorption in the proximal tubule [7–9], loop of Henle
[10], or collecting duct [11, 12]. In experimental animals, NO
contributes to adapting renal function to changes in dietary salt
intake [13–15].
Infusions of L-arginine in experimental animals can increase
renal blood flow (RBF) and induce natriuresis and diuresis [13,
16–18]. L-arginine microperfused into the macula densa segment
of the nephron inhibits afferent arteriolar vasoconstriction and
blunts the tubuloglomerular feedback (TGF) response [18]. These
renal effects of L-arginine appear to be mediated by NO gener-
ation since they are stereo-specific and are blocked by inhibitors
of NOS [18]. Dietary salt restriction increases the sensitivity of the
rat kidney to L-arginine-induced renal vasodilation, suggesting
that the renal effects of L-arginine are determined by dietary salt
[13]. Infusion of L-arginine has variable effects on the renal vascular
resistance and the glomerular filtration rate (GFR) of normal human
subjects [19] and those with hypertension [19–21]. It increases the
sodium excretion (UNaV) moderately in fluid loaded subjects [20]
and hypertensive patients on an unrestricted salt intake [22].
L-arginine can reduce UNaV by other mechanisms, some of
which do not depend on NO generation in the kidney. It stimu-
lates insulin secretion [23–26], which enhances tubular sodium
reabsorption in the distal nephron [27–31]. Arginine decarboxyl-
ase is heavily expressed in the proximal tubules of the kidney,
where it metabolizes L-arginine to agmatine, which enhances
proximal tubule Na reabsorption [32].
L-arginine can prevent or reverse hypertension in the Dahl salt
sensitive rat [33], and can improve endothelial dysfunction in
patients with hypercholesterolemia [34]. In view of these poten-
tially important roles for L-arginine in adapting renal and endo-
thelial function in health and disease, and the indication that its
effects in animals are dependent on salt intake, the present studies
were undertaken to investigate the effects of L-arginine on renal
hemodynamics and sodium reabsorption in normal human sub-
jects during changes in dietary salt. In this study, L-arginine was
infused into normal human volunteers equilibrated to a high or
low salt intake and the response was compared to a control
infusion of branched chain amino acids that have little or no effect
on blood pressure (BP), renal hemodynamics, cGMP or NO2 1
NO3 (Nox) [35, 36]. Lithium clearance was used as a marker of
proximal reabsorption [37]. The studies were designed to test the
hypothesis that the renal response to L-arginine in normal human
subjects depends on the level of dietary salt intake.
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METHODS
Subjects
Studies were conducted on eight normal human volunteers who
gave informed consent. There were five males and three females
whose average age was 39 years (range 23 to 59 years). Seven
subjects were white and one was African American. Their weight
averaged 68.5 6 3.5 kg (mean 6 SEM). None were more than 20%
outside calculated ideal weight for height. The studies were
approved by the Institutional Review Board at the Georgetown
University Medical Center. Subjects were in good health and
consumed no drugs. None had a history of hypertension, cardio-
vascular disease, diabetes mellitus or hypercholesterolemia. All
had normal blood pressures. None was a smoker and none
consumed more than one alcoholic drink daily.
Protocol
After a full medical history and physical examination, subjects
were admitted to the Clinical Research Center for a 14-day period
where they ate the same food each day so as to provide a highly
regulated dietary intake. This diet was calculated to provide each
24 hours: 15 to 25 mmol of sodium, 60 to 75 mmol of potassium
and 1.0 to 1.2 g z kg21 of protein. It contained no processed food.
For one week this was supplemented with ten 1 g tablets of NaCl
to give a high salt intake of 185 to 195 mmol z 24 hr21. Since
subjects easily recognize the taste of salt, a double-blind placebo
control was not possible. Fluids were allowed ad libitum but
caffeinated beverages, alcohol and smoking were forbidden. Sub-
jects spent the 14 days of the study at the Clinical Research Center
to ensure dietary compliance.
Days 6 to 7 and 13 to 14 were experimental days. On the night
before, subjects received 400 mg of lithium chloride. On the
experiment day, they were fasting. During the high salt period,
they received their normal breakfast salt intake of 3 g of NaCl as
330 ml of 0.154 M NaCl solution infused intravenously and during
low salt intake, they received a similar quantity of 5 g z 100 g21
dextrose solution. These infusions were given two hours before
the basal period commenced. The dextrose infusion was given to
match the fluid load provided in the NaCl infusion. The quantity
of dextrose infused was moderate (17 g) and was calculated to be
sufficiently far ahead of the blood sampling to have a little effect
in stimulating insulin secretion. A forearm vein was cannulated
for infusion and a vein in the contralateral arm cannulated for
blood sampling. Subjects were seated except while voiding their
bladder. Blood pressure (BP) and heart rate (HR) were recorded
automatically (Dynamap Inc.) at 10 minute intervals during the
basal and experimental periods, and the data were averaged.
Subjects were fluid loaded with 15 ml z kg21 of water and
additional quantities were given each half hour equivalent to the
volume of urine passed. Water loading was undertaken as in
previous protocols to provide a uniform diuresis to facilitate
clearance measurements. Subjects received a constant intrave-
nous infusion at 1 ml z min21 of 5 g z 100 g21 dextrose solution
containing inulin (46 mg z ml21) and paraaminohippuric acid
(PAH 18 mg z ml21) after a loading dose of 50 ml of this solution.
After one hour of equilibration, there was a one hour clearance
period with blood sampling at the midpoint (basal period).
Thereafter, subjects received an intravenous infusion of either
L-arginine (30 g in 750 ml of water; R-Gene 4% solution) or
branched chain amino acids (30 g in 750 ml of water; BranchAmin
4% solution) delivered over 15 minutes. The experimental clear-
ance period of 60 minutes commenced at the beginning of this
infusion. The order of salt intake, and the order of infusion of
L-arginine or branched chain amino acids at each salt intake were
randomized between subjects using a Latin square technique.
Chemical methods
These were as described previously [38]. Sodium, potassium
and lithium concentrations were measured in a flame photometer
with caesium as an internal standard (IL 943; Instrument Labo-
ratory Inc.). Inulin and PAH were measured colorimetrically.
Urine for cGMP concentration and plasma for insulin concentra-
tion were assayed using ELISA methods (Cyclic GMP Enzyme
Assay Kit; Caymon Chemical Company, Ann Arbor, MI and
Insulin Clinical Assays, Baxter and Travenol, Cambridge, MA,
USA). Blood for plasma renin activity (PRA) was taken into
chilled EDTA-containing tubes and the plasma separated prior to
subsequent assay for angiotensin I generation over 90 minutes at
37°C. Urine for NO2 1 NO3 (NOx) was collected into containers
containing penicillin G (1 M units) prior to the assay by chemilu-
minesence (Siever Inc.). All plasma and urine samples for hor-
mone assay were stored at 270°C.
Calculation of results
The glomerular filtration rate (GFR) was taken as the clearance
of inulin and the effective renal plasma flow (RPF) as the
clearance of PAH. The clearance of lithium (Li) was used to
calculate proximal reabsorption using formulae described previ-
ously [37, 39].
Statistical methods
Mean 6 SEM values were computed. For each variable, the
change produced during L-arginine infusion (experimental re-
sponse) was compared to that during branched chain amino acid
infusion (control response) at high and low levels of salt intake.
An analysis of variance (ANOVA) was undertaken to assess the
effects of L-arginine infusion, salt intake, and salt intake on the
response to arginine (interaction). Data were considered statisti-
cally significant at P , 0.05.
RESULTS
All eight subjects successfully completed the high and low salt
period of the protocol without encountering adverse effects. As
shown in Table 1, there were no significant effects of L-arginine
on systolic or diastolic blood pressure. The heart rate was lower
during the high salt period. It was significantly different during
L-arginine and branched chain amino acid infusions because of a
reduction during infusion of branched chain amino acid that was
not seen during the L-arginine infusion.
The excretion of NOx was not affected by salt intake, but was
increased significantly by L-arginine (Table 2). The excretion of
cGMP was increased by high salt intake and by L-arginine
infusion; the effect of L-arginine on cGMP was enhanced signif-
icantly by the high salt intake. The PRA was decreased during
high salt intake but was not significantly modified by the infusions.
Plasma insulin concentration was not significantly altered by salt
intake but was increased by L-arginine infusion independent of
salt intake.
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The GFR and RPF were increased during the high salt intake,
but neither was significantly changed by the L-arginine infusion
(Table 3).
Salt intake and L-arginine infusion had substantial and inter-
active effects on sodium excretion and reabsorption without
affecting potassium excretion (Table 4). During the high salt
intake both absolute and fractional Na excretions were increased
compared to those during the low salt intake. This was accompa-
nied by a decreased rate of calculated fractional Na reabsorption
in the proximal and distal nephrons. Infusion of L-arginine
increased sodium excretion by 80% during the high salt intake,
but reduced it by 50% compared to the branched chain amino
acid infusion during the low salt intake. During the low salt intake,
the L-arginine-induced decrease in sodium excretion was accom-
panied by an increased fractional sodium reabsorption in the
proximal and distal nephrons (calculated from lithium and sodium
clearances) from 77.0 6 2.8% to 83.7 6 2.5% and from 98.0 6
0.5% to 98.7 6 0.5%, respectively. During the high salt intake, the
Table 1. Systolic and diastolic blood pressures and heart rate during infusion of L-arginine or branched chain amino acids: Effects of salt intake
Measure
Salt
intake
L-arginine infusion BCAA infusion
Effects
of salt
Effects of
L-Arg vs.
BCAA
Effect of salt
on L-Arg
responseBefore During Change Before During Change
SBP LS 109 6 4 108 6 3 21 6 2 117 6 4 114 6 3 22 6 3
mm Hg NS NS NS
HS 115 6 5 113 6 4 23 6 2 117 6 4 120 6 4 12 6 3
DBP LS 68 6 3 63 6 2 25 6 3 71 6 2 69 6 2 23 6 1
mm Hg NS NS NS
HS 67 6 3 65 6 3 22 6 2 68 6 3 69 6 2 11 6 2
Heart rate LS 68 6 3 65 6 4 23 6 2 71 6 3 63 6 3 28 6 1
min21 P , 0.05 P , 0.05a NS
HS 62 6 4 62 6 4 0 6 2 64 6 3 59 6 2 25 6 1
Data are mean 6 SEM values. Abbreviations are: BCAA, branched chain amino acids; L-Arg, L-arginine; LS, low salt intake; HS, high salt intake;
SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant. Statistical analysis is from the results of ANOVA.
a The significant effect of L-arginine is apparent because of a reduction in heart rate with BCAA, but not because of a significant change during
L-arginine.
Table 2. Excretion of nitrite 1 nitrate and cyclic GMP, and plasma renin activity and insulin during infusion of L-arginine and branched chain
amino acids: Effects of salt intake
Measure
Salt
intake
L-arginine infusion BCAA infusion
Effects
of salt
Effects of
L-Arg vs.
BCAA
Effects of salt
on L-Arg
responseBefore During Change Before During Change
NOx excretion LS 157 6 46 210 6 48 154 6 13 173 6 28 183 6 52 110 6 33
nmol z min21 NS P , 0.05 NS
HS 138 6 30 182 6 70 143 6 66 176 6 42 188 6 29 112 6 22
cGMP excretion LS 256 6 64 337 6 76 181 6 25 277 6 45 294 6 49 116 6 26
pg z min21 P , 0.05 P , 0.05 P , 0.05
HS 311 6 68 563 6 93 1252 6 59 384 6 79 342 6 69 242 6 53
PRA LS 6.2 6 1.7 7.5 6 2.8 11.3 6 12 4.7 6 1.6 3.5 6 1.0 21.3 6 0.8
ng z ml21 z hr21 P , 0.05 NS NS
HS 1.5 6 0.3 1.9 6 0.4 10.5 6 0.2 1.5 6 0.4 1.3 6 0.2 20.2 6 0.1
Plasma insulin LS 67 6 7 92 6 13 125 6 11 64 6 7 66 6 6 12 6 8
ng z ml21 NS P , 0.05 NS
HS 66 6 7 76 6 9 110 6 5 62 6 8 65 6 7 13 6 7
Data are mean 6 SEM values. Abbreviations are: BCAA, branched chain amino acids; L-Arg, L-arginine; LS, low salt intake; HS, high salt intake;
NOx, NO2 1 NO3; PRA, plasma renin activity.
Table 3. Glomerular filtration rate and effective renal plasma flow during infusion of L-arginine and branched chain amino acids: Effects of salt
intake
Measure
Salt
intake
L-arginine infusion BCAA infusion
Effects
of salt
Effects of
L-Arg vs.
BCAA
Effects of salt
on L-Arg
responseBefore During Change Before During Change
GFR LS 83.5 6 9.1 99.4 6 4.8 115.9 6 6.4 92.6 6 10.5 98.8 6 7.5 16.0 6 9.6
ml z min21/1.73 m2 P , 0.05 NS NS
HS 93.0 6 6.8 100.1 6 11.9 17.1 6 11.6 93.9 6 7.5 104.1 6 8.9 110.3 6 8.3
RPF LS 349 6 35 399 6 28 150 6 25 383 6 63 378 6 77 26 6 75
ml z min21/1.73 m2 P , 0.05 NS NS
HS 426 6 47 613 6 87 1187 6 67 514 6 85 546 6 64 132 6 37
Data are mean 6 SEM values. Abbreviations are: BCAA, branch chain amino acids; L-Arg, L-arginine; GFR, glomerular filtration rate; RPF, effective
renal plasma flow.
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L-arginine-induced increase in sodium excretion was accompa-
nied by a decreased fractional sodium reabsorption in the proxi-
mal and distal nephrons from 76.9 6 3.3% to 72.3 6 2.7% and
from 89.5 6 1.9% to 83.7 6 2.4%, respectively. In contrast,
fractional proximal and distal reabsorption was quite constant
during the infusion of branched chain amino acids. The ANOVA
calculation demonstrated that these effects of salt on fractional
reabsorption with L-arginine compared to branched chain amino
acids were statistically significant (Table 4). Potassium excretion
was not significantly altered by salt intake or L-arginine infusion.
DISCUSSION
The main new finding of this randomized, cross over, placebo-
controlled study was that L-arginine had opposite effects on
tubular reabsorption depending on the level of dietary salt intake.
During the high salt intake it blunted fractional sodium reabsorp-
tion in the proximal and distal nephrons as assessed by the sodium
and lithium clearance method. In contrast, during the low salt
intake it enhanced fractional sodium reabsorption in both the
proximal and distal nephrons. Thus, it appears that L-arginine
infusion augments the normal physiological response of the
kidney to different levels of sodium intake.
Infusion of L-arginine into normotensive volunteers has a quite
variable effect on blood pressure (BP) and glomerular filtration
rate (GFR) [36, 40–44]. We detected no significant effect on BP,
GFR, or renal plasma flow (RPF). A hypotensive response to
L-arginine with an increase in renal blood flow has been found in
some studies in patients with hypertension [19, 21, 45], but not
others [20], and may depend on the patient’s age [22]. Moreover,
there was a trend toward an increase in RPF with L-arginine in
this study. Thus, hemodynamic effects of L-arginine could have
contributed significantly to changes in sodium excretion. Any
increase in RPF during high salt intake without a corresponding
change in GFR could reduce the filtration fraction, which is
associated with a reduction in proximal fluid reabsorption. In
confirmation of previous studies in normal subjects [46] we found
no consistent changes in PRA with L-arginine. Therefore, the
renin-angiotensin system is unlikely to have contributed to
changes in sodium excretion.
Arginine is used to acidify the urine to enhance the elimination
of basic drugs [47]. It is not clear whether urinary acidification per
se would alter sodium excretion. Studies in rats have shown that,
under condition of rigorous dietary control, supplementation with
NaCl increases NO generation and action, as indexed by increased
excretion of NOx and cGMP and increased renal vasoconstriction
in response to NOS inhibition [14, 15]. In human subjects much of
the urinary NOx derives from dietary sources [48]. This might
explain why salt intake did not significantly modify steady state
rates of NOx excretion in the present study, whereas it has a
consistent effect in rats. Alternatively, there may be species
differences or the sodium intake in this study, although encom-
passing much of normal range, may not have been sufficiently
large. Of interest was the finding that cGMP excretion increased
with salt intake, which could reflect an increase in NO generation.
However, it could also be secondary to an increase in ANP since
both NO and ANP enhance cGMP excretion [49].
In agreement with previous studies [23–26], plasma insulin
concentration was increased significantly by L-arginine infusion
but not during branched chain amino acid infusion. This increase
was seen during both high and low salt intakes (Table 2). The
ability of insulin to decrease urinary sodium excretion has been
recognized for more than 60 years [50]. Using the euglycemic
clamp method in normal human volunteers to increase their
plasma insulin by tenfold independent of plasma glucose, hyper-
insulinemia was associated with an immediate and persistent fall
in sodium excretion that was independent of renal hemodynamics,
or catecholamines, and was accompanied by a marked increase in
fractional distal sodium reabsorption [27]. However, plasma insu-
lin concentrations increased with L-arginine at both levels of salt
intake, yet distal sodium reabsorption increased only during the
low salt intake. This suggests that changes in plasma insulin were
not of predominant importance in this study. Norgaard et al [31]
found that insulin infusion into normal human subjects increased
Table 4. Sodium and potassium excretion, fractional excretion of sodium, and fractional proximal and distal sodium reabsorption during infusion
of L-arginine and branched chain amino acids: Effects of salt intake
Measure
Salt
intake
L-arginine infusion BCAA infusion
Effects
of salt
Effects of
L-Arg vs.
BCAA
Effects of salt
on L-Arg
responseBefore During Change Before During Change
UNaV LS 45 6 5 21 6 3 224 6 4 45 6 7 44 6 6 21 6 7
mmol z min21 P , 0.05 P , 0.05 P , 0.05
HS 298 6 56 537 6 84 1240 6 62 223 6 65 215 6 47 28 6 38
UKV LS 42 6 9 32 6 4 210 6 7 36 6 4 33 6 4 23 6 6
mmol z min21 NS NS NS
HS 39 6 6 41 6 9 13 6 7 36 6 7 32 6 5 24 6 7
FENa % LS 0.41 6 0.06 0.16 6 0.03 20.25 6 0.05 0.38 6 0.07 0.34 6 0.06 20.04 6 0.06
P , 0.05 P , 0.05 P , 0.05
HS 2.24 6 0.38 3.78 6 0.48 11.54 6 0.13 1.67 6 0.41 1.51 6 0.34 20.16 6 0.29
FPRNa % LS 77.0 6 2.8 83.7 6 2.5 16.7 6 2.4 79.3 6 1.0 79.2 6 2.1 20.1 6 2.2
P , 0.05 NS P , 0.05
HS 76.9 6 3.3 72.3 6 2.7 24.6 6 2.0 75.7 6 2.7 75.6 6 2.3 20.2 6 3.9
FDRNa % LS 98.0 6 0.5 98.7 6 0.5 10.8 6 0.3 98.2 6 0.3 98.3 6 0.3 10.1 6 0.3
P , 0.05 NS P , 0.05
HS 89.5 6 1.9 83.7 6 2.4 25.8 6 1.3 93.2 6 1.7 93.6 6 1.3 10.4 6 1.2
Data are mean 6 SEM values. Abbreviations are: BCAA, branch chain amino acids; L-Arg, L-arginine; LS, low salt intake; HS, high salt intake; FENa,
fractional excretion of Na; FPRNa, fractional proximal reabsorption; FDRNa, fractional distal sodium reabsorption.
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the fractional distal reabsorption of sodium, but when superim-
posed on extracellular fluid volume expansion, insulin decreased
it. Thus, insulin may have contributed to the increase in fractional
distal reabsorption seen with L-arginine during the low salt intake.
The L-arginine-induced changes in proximal reabsorption cannot
be ascribed to insulin and require an additional explanation.
L-arginine infusion increased renal excretion of both NOx and
cGMP. L-arginine infusion causes a modest increase in plasma
ANP levels in humans [46]. Therefore, the increase in excretion of
NOx and cGMP suggests that L-arginine enhanced NO generation
and/or ANP secretion and their action on guanylate cyclase. The
high salt intake enhanced the effects of L-arginine on cGMP
excretion. The proximal tubule of the normal rat is a site of
mRNA expression for both the constitutive, endothelial-type NOS
[51] and the inducible-type NOS [52, 53]. Studies in experimental
animals using NO donors or NOS inhibitors have concluded that
NO, or its second messenger, cGMP, can inhibit sodium and
bicarbonate absorption from the rabbit proximal tubule [9],
inhibit Na,K-ATPase in the mouse proximal tubule [54], inhibit
proximal Na reabsorption as indexed by lithium clearance [55, 56],
and mediate some of the effects of ECV expansion to diminish
proximal reabsorption [8, 56, 57]. One study found that blockade
of NOS inhibited proximal reabsorption in the euvolemic rat [57].
Thus, some of these data are consistent with a role for NO
generation from L-arginine in blunting proximal reabsorption
during a high salt intake. Studies in normal human subjects
receiving a normal or unrestricted salt intake have shown that
infusion of L-arginine increases UNaV [20, 50, 22]. Amino acid
infusions also increase excretion of Na and cGMP and diminish
fractional proximal Na reabsorption [39]. Generation of cGMP
can disrupt proximal glomerulo-tubular balance [39]. The present
study shows that L-arginine, infused during a high salt intake, also
increased cGMP excretion and reduced fractional proximal reab-
sorption, which implies that it impaired proximal glomerulo-
tubular balance. However, the explanation for the enhancement
of fractional proximal reabsorption with L-arginine during a low
salt intake is not clear. It is probably not due to a failure of
L-arginine infusion to enhance NO generation, since the excretion
of NOx and cGMP were both increased by L-arginine during the
low salt intake. Studies in the rat have shown that NO acts as a
powerful physiological antagonist to the effects of angiotensin II
on proximal reabsorption [56, 57]. This may explain why, during a
low salt intake when angiotensin II levels may be increased to a
level that could impair proximal reabsorption [57], L-arginine-
induced NO generation led to an increase in proximal reabsorp-
tion. In the present study, salt restriction increased plasma renin
activity two- to fourfold, implying a substantial stimulation of the
renin-angiotensin system. Alternatively, it may be that L-arginine
metabolism by arginine decarboxylase to agmatine may explain
the enhanced proximal reabsorption in this setting [32].
In conclusion, this study in normal human subjects has detected
a previously unrecognized effect of salt intake on the tubular
response to L-arginine. L-arginine infusion augments the ex-
pected physiological response by decreasing sodium reabsorption
in the proximal and distal nephrons during a high salt intake, but
L-arginine increases sodium reabsorption at these sites with a low
salt intake. These effects appear independent of blood pressure,
renal hemodynamics, or the renin-angiotensin system. They likely
represent complex, interactive effects of NO and ANP that
stimulate cGMP and generally impair Na reabsorption, in concert
with release of insulin and other hormones that can enhance Na
reabsorption.
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APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; ANOVA,
analysis of variance; Li, lithium; BP, blood pressure; GFR, glomerular
filtration rate; HR, heart rate; HS, high salt diet; LS, low salt diet; NO,
nitric oxide; NOS, nitric oxide synthase; NOx, NO2 1 NO3; RBF, renal
blood flow; PAH, paraaminohippuric acid; PRA, plasma renin activity;
RPF, renal plasma flow; TGF, tubuloglomerular feedback; UNaV, urinary
sodium excretion.
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